For MZ SR:
Director-General of the Pharmacy and Drug Section Policy MUDr. Adam Hlôška
Director of the Division of Classification, Pricing; and PharmDr. Rastislav Pullmann
a department of classification, pricing and PharmDr. Ľubomír Tomčíková, CSc.
For Johnson & Johnson, Ltd.
RNDr. Vladimir Devečka, CSc.
PharmDr. Anna Shuvad
The meeting took place at the request of the company Johnson & Johnson, s.r.o., who requested a business meeting.
The meeting was opened by the Section Director-General pharmacy and drug policy MUDr. Adam Hlôška.
Johnson & Johnson, Ltd.:
The reason for requesting a meeting was Discussion of the next procedure before the end of the period conditional categorization of 10799 Zytiga 250 mg tablets tbl 120x250 mg which was conditional included in the list of categorised medicinal products with It shall apply from 1.10.2014.
For MZ SR:
MZ SR will proceed in accordance with the current Law No 363/2011 Z.z. on the scope and the conditions for reimbursement of medicinal products, medical devices; and dietetic foods based on public health insurance and amendment certain laws.
The sitting was closed by the Director-General of the Department of Pharmacy Dr. Adam Hlôška.
She wrote: PharmDr. Lubomir Tomčíková, CSc.
Verified for Johnson & Johnson s.r.o.: PharmDr. Anna Shuvad
Approval: MUDr. Adam Hlôška
Date: 13.10.2015